CD274 and melanoma: As such, the therapeutic efficacy of PD1/PD-L1 signaling inhibitors especially the mAbs against PD-1 (such as Nivolumab) has been tested in various stages of clinical trials in patients with non-small cell lung cancer, melanoma and renal cancer, but the outcomes were disappointing [77, 78].